FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE PR Newswire THOUSAND OAKS...
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024 PR Newswire THOUSAND OAKS, Calif., June 12, 2024 Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA® and Progress...
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., June 5, 2024 THOUSAND OAKS, Calif., June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN...
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) PR Newswire THOUSAND OAKS...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -4.34 | -1.22744499123 | 353.58 | 362.59 | 341.27 | 0 | 0 | IX |
4 | 22.04 | 6.73594132029 | 327.2 | 370.38 | 324.57 | 0 | 0 | IX |
12 | 26.88 | 8.33850353642 | 322.36 | 370.38 | 317.29 | 0 | 0 | IX |
26 | 89.72 | 34.5715166461 | 259.52 | 370.38 | 241.31 | 0 | 0 | IX |
52 | 70.26 | 25.1846010467 | 278.98 | 370.38 | 240.95 | 0 | 0 | IX |
156 | 50.84 | 17.0375335121 | 298.4 | 379.22 | 227.92 | 0 | 0 | IX |
260 | 97.01 | 38.4609285176 | 252.23 | 392.5 | 167.32 | 0 | 0 | IX |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.